Replies to post #248395 on NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

It could well be more revealing at Dr Bosch's presentation. I am particularly interested in this part of the synopsis "Outlining the key aspects of the DCVax technology that contribute to the positive clinical results"

December 10 2019

11:40 am DCVax Technology: Leveraging Activated Dentritic Cells in Clinical 40 for GBM
Marnix Bosch
CTO, Northwest Biotherapeutics

Synopsis
Exploring the history, biology and development of the platform technology DCVax
Outlining the key aspects of the DCVax technology that contribute to the positive clinical results
Designed to mobilize the entire immune system
Designed to target not just one but the full set of biomarkers on the patient’s tumor
DCVax is personalized, and targets the particular biomarkers expressed on that patient’s tumor
Pinpointing highs and lows of clinical development to date

https://glioblastoma-drugdevelopment.com/about/agenda/